Targeted drugs such as bevacizumab (anti-angiogenic factor), alectinib (ALK gene), and everolimus (mTOR inhibitor), have been successively used in the precise treatment of GBM, and significantly improved progression-free survival (PFS) in GBM patients (3, 4). This evidence concerns the gene ALK and glioblastoma.